Stock 4171 GENEREACH BIOTECHNOLOGY CORP.
Add to a list
To use this feature you must be a member
Log inSign up

GeneReach Biotechnology Corp.

Equities

4171

TW0004171004

Pharmaceuticals

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
31.95 TWD +0.47% Intraday chart for GeneReach Biotechnology Corp. +5.10% -19.01%
Mar. 28 GeneReach Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 GeneReach Biotechnology Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about GeneReach Biotechnology Corp.

GeneReach Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
GeneReach Biotechnology Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
GeneReach Biotechnology Corp.(TPEX:4171) dropped from S&P Global BMI Index CI
GeneReach Biotechnology Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
GeneReach Biotechnology Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
GeneReach Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
GeneReach Biotechnology Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
GeneReach Biotechnology Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
GeneReach Biotechnology Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
GeneReach Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Taiwan's OBI Pharma Grants Experimental Drug Rights to Odeon Therapeutics (Hong Kong) MT
GeneReach Biotechnology Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Genereach Biotechnology Corp. Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Genereach Biotechnology Corp. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Genereach Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Genereach Biotechnology Corp. Reports Earnings Results for the Third Quarter Ended September 30, 2020 CI
GeneReach Biotechnology Corp.(GTSM:4171) added to S&P Global BMI Index CI
Genereach Biotechnology Corp. Reports Earnings Results for the Second Quarter Ended June 30, 2020 CI
Genereach Biotechnology Corp. Reports Earnings Results for the First Quarter Ended March 31, 2020 CI
Genereach Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2019 CI
Genereach Biotechnology Corp. Reports Earnings Results for the Third Quarter Ended September 30, 2019 CI
Genereach Biotechnology Corp. Reports Earnings Results for the Second Quarter Ended June 30, 2019 CI
Genereach Biotechnology Corp. Reports Earnings Results for the First Quarter Ended March 31, 2019 CI
Genereach Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2018 CI
Genereach Biotechnology Corp. Reports Earnings Results for the Third Quarter Ended September 30, 2018 CI

Chart GeneReach Biotechnology Corp.

Chart GeneReach Biotechnology Corp.
More charts

Company Profile

GeneReach Biotechnology Corp. is principally engaged in the manufacture and distribution of animal testing equipment and testing agents. The Company mainly operates through Taiwan segment. The Company provides shrimp virus testing agents, on-site detection systems for fish and shrimp, mini centrifugal machines, pet disease testing agents and other testing equipment.
Sector
Pharmaceuticals
More about the company

Income Statement Evolution

More financial data
  1. Stock Market
  2. Equities
  3. 4171 Stock
  4. News GeneReach Biotechnology Corp.
  5. Taiwan's OBI Pharma Grants Experimental Drug Rights to Odeon Therapeutics (Hong Kong)